In the first edition of the interview series, we spoke with FogPharma’s Chief Scientific Officer, Howard Stern.
As a leading figure in drugging the “undruggable”, Howard shares some fascinating insights into how FogPharma is unlocking new drug targets and gives his take on this area of R&D.
Topics covered include:
How are you working to overcome the major limiting factors of using Helicon™ peptides?
Outside of your area of focus, what areas of “undruggable” research are you most excited about?
What conversations need to happen to advance the “undruggable” industry?